Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Avacta Group plc ( (GB:AVCT) ).
Avacta Group PLC announced an upcoming investor webinar featuring presentations by CEO Dr. Christina Coughlin and CSO Michelle Morrow. The webinar will discuss recent data on Avacta’s pre|CISION® candidates, FAP-Dox (AVA6000) and FAP-EXd (AVA6103), presented at the AACR Annual Meeting. This event highlights Avacta’s commitment to engaging with investors and showcasing its advancements in targeted cancer therapies, potentially strengthening its market position and stakeholder confidence.
The most recent analyst rating on (GB:AVCT) stock is a Buy with a £105.0000 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on expanding the reach of potent cancer therapies through its proprietary pre|CISION® platform. This platform utilizes a tumor-specific protease to deliver highly potent payloads directly to tumors, minimizing exposure to healthy tissues. The company’s innovative pipeline includes peptide drug conjugates and Affimer® drug conjugates, offering advantages over traditional antibody drug conjugates.
Average Trading Volume: 1,952,982
Technical Sentiment Signal: Sell
Current Market Cap: £125.6M
See more insights into AVCT stock on TipRanks’ Stock Analysis page.